NKGen Biotech adds $295K to AlpineBrook secured note, principal now $26.1M

NKGen Biotech, Inc.

Amendment to secured promissory note increases principal by $295,000 to $26,135,106.
Interest on original $25,840,106 accrues from Jan 5, 2026; on additional $295,000 from Jan 12, 2026.
Lender is AlpineBrook Capital GP I Limited; borrows are NKGen Biotech and NKGen Operating Biotech.
All other terms of the January 5, 2026 note remain unchanged.

item 1.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. amended Amendment with AlpineBrook Capital GP I Limited valued at $295,000 (effective 2026-01-12).

Action: amendment
Agreement: credit facility
Counterparty: AlpineBrook Capital GP I Limited
Value: $295,000
Effective: 2026-01-12

Exact text from the filing

On January 12, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “ Borrowers ”), entered into an amendment (the “ Amendment ”) to that certain secured promissory note with AlpineBrook Capital GP I Limited (the “ Lender ”), dated January 5, 2026 (the “ Note ”).

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-26-005260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.